XML 16 R2.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended |  |  |  |  |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Oct. 01, 2023 | Jul. 01, 2023 | Apr. 01, 2023 | Oct. 01, 2022 | Jul. 01, 2022 | Apr. 01, 2022 | Oct. 01, 2021 | Jul. 01, 2021 | Apr. 01, 2021 | Oct. 01, 2020 | Jul. 01, 2020 | Apr. 01, 2020 | Dec. 31, 2019
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure, Table | Pay Versus Performance The Company’s compensation objectives and philosophy, which are discussed above, are designed to reward the contributions of its NEOs to the Company’s financial performance and provide compensation which is sufficient to attract and retain individuals who are motivated to contribute to the Company’s financial performance. To achieve these goals, the Company has implemented incentive plans which tie a significant portion of each NEOs compensation to pre-determined financial goals. For the year ended December 31, 2023, the most important financial performance measure used by the Company to link executive compensation actually paid to the executive officers was Adjusted EBITDA. For the years ended December 31, 2022, 2021, and 2020, the most important financial performance measure used by the Company to link executive compensation actually paid to the executive officers was Operating Results, which is described in the accompanying footnotes below. The following table summarizes the executive compensation earned by the Company’s Principal Executive Officer (“PEO”), and other Named Executive Officers (“NEOs”), the executive compensation actually paid to the Company’s PEO and other NEOs, and certain financial performance measures of the Company for the years ended December 31, 2023, 2022, 2021, and 2020.
Year(1) | ​ | ​ | Summary Compensation Table Total for PEO(1) ($) | ​ | ​ | Compensation Actually Paid to PEO(5) ($) | ​ | ​ | Average Summary Compensation Table Total for non-PEO NEOs(1) ($) | ​ | ​ | Average Compensation Actually Paid to non-PEO NEOs(5) ($) | ​ | ​ | Value of Initial Fixed $100 Investment Based on | ​ | ​ | Net Income(2) ($) | ​ | ​ | Operating Results(3) ($) | ​ | ​ | Adjusted EBITDA(6) ($)
​ | Total Shareholder Return ($) | ​ | ​ | Peer Group Total Shareholder Return(4) ($) | ​
2023 | ​ | ​ | $3,372,377 | ​ | ​ | 3,822,626 | ​ | ​ | $1,722,785 | ​ | ​ | 1,865,290 | ​ | ​ | 81 | ​ | ​ | 134 | ​ | ​ | 37,220,000 | ​ | ​ | 36,265,000 | ​ | ​ | 77,717,000
2022 | ​ | ​ | 2,408,584 | ​ | ​ | 1,859,559 | ​ | ​ | 1,122,465 | ​ | ​ | 920,090 | ​ | ​ | 71 | ​ | ​ | 130 | ​ | ​ | 43,407,000 | ​ | ​ | 35,034,000 | ​ | ​ | 73,661,000
2021 | ​ | ​ | 4,143,576 | ​ | ​ | 3,275,545 | ​ | ​ | 1,454,841 | ​ | ​ | 1,110,753 | ​ | ​ | 84 | ​ | ​ | 135 | ​ | ​ | 57,924,000 | ​ | ​ | 43,732,000 | ​ | ​ | 73,780,000
2020 | ​ | ​ | 2,961,147 | ​ | ​ | 2,446,657 | ​ | ​ | 1,056,375 | ​ | ​ | 829,949 | ​ | ​ | 105 | ​ | ​ | 111 | ​ | ​ | 52,491,000 | ​ | ​ | 38,435,000 | ​ | ​ | 70,017,000
1) | The PEO is Christopher J. Reading for each of the years presented. The non-PEO NEOs are Carey P. Hendrickson, Eric J. Williams, Graham D. Reeve, and Richard Binstein for the years 2023 and 2022, Carey P. Hendrickson, Eric J. Williams, Glenn D. McDowell, and Graham D. Reeve for 2021 and Carey P. Hendrickson, Lawrance W. MacAfee, Glenn D. McDowell, and Graham D. Reeve for 2020.
2) | Net income includes earnings attributable to non-controlling interests.
3) | Operating Results, a non-GAAP measure, equals net income attributable to our stockholders less non-cash asset impairment charge, changes in revaluation of put-right liability, Relief Funds, changes in fair value of contingent earn-out consideration, and any allocations to non-controlling interests, all net of taxes. For additional information regarding Operating Results, please see Item 7 in the Company’s Form 10-K filed with the SEC on February 29, 2024.
4) | Total Shareholder Return assumes that $100 was invested in our common stock and the common stock on each of the companies listed on The NYSE Heathcare Index (the Company’s Peer Group), on December 31, 2019, and that any dividends were reinvested.
5) | For a computation of compensation actually paid to PEO and average compensation actually paid to non-PE NEOs, please refer to the subsequent table.
6) | For additional information regarding Adjusted EBITDA, please see Item 7 in the Company’s Form 10-K filed with the SEC on February 29, 2024.
The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table on page 31, to derive the compensation actually paid to the Company’s PEO and other NEOs.
| ​ | ​ | Adjustments | ​
Year | ​ | ​ | Summary Compensation Table Total ($) | ​ | ​ | Less: Reported Value of Stock Awards ($)(1) | ​ | ​ | Plus: Year End Fair Value of Restricted Stock Awards Granted During the Year ($)(2)(3) | ​ | ​ | Plus: Change in Fair Value of Outstanding and Unvested Restricted Stock Awards ($)(2)(3) | ​ | ​ | Plus: Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year ($)(2)(3) | ​ | ​ | Dividends paid on Unvested Restricted Stock Awards During the Fiscal Year ($)(4) | ​ | ​ | Compensation Actually Paid ($) | ​
PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
2023 | ​ | ​ | 3,372,377 | ​ | ​ | 1,632,482 | ​ | ​ | 1,508,868 | ​ | ​ | 288,036 | ​ | ​ | 235,956 | ​ | ​ | 49,871 | ​ | ​ | 3,822,626 | ​
2022 | ​ | ​ | 2,408,584 | ​ | ​ | 1,016,800 | ​ | ​ | 810,300 | ​ | ​ | (411,395) | ​ | ​ | 22,404 | ​ | ​ | 46,466 | ​ | ​ | 1,859,559 | ​
2021 | ​ | ​ | 4,143,576 | ​ | ​ | 2,120,100 | ​ | ​ | 1,911,000 | ​ | ​ | (613,844) | ​ | ​ | (81,371) | ​ | ​ | 36,284 | ​ | ​ | 3,275,545 | ​
2020 | ​ | ​ | 2,961,147 | ​ | ​ | 1,533,056 | ​ | ​ | 1,346,800 | ​ | ​ | 180,251 | ​ | ​ | (518,261) | ​ | ​ | 9,776 | ​ | ​ | 2,446,657 | ​
Non-PEO NEOs | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2023 | ​ | ​ | 1,722,785 | ​ | ​ | 816,241 | ​ | ​ | 754,434 | ​ | ​ | 108,759 | ​ | ​ | 76,874 | ​ | ​ | 18,679 | ​ | ​ | 1,865,290 | ​
2022 | ​ | ​ | 1,122,465 | ​ | ​ | 444,850 | ​ | ​ | 354,506 | ​ | ​ | (132,671) | ​ | ​ | 5,768 | ​ | ​ | 14,872 | ​ | ​ | 920,090 | ​
2021 | ​ | ​ | 1,454,841 | ​ | ​ | 706,539 | ​ | ​ | 537,469 | ​ | ​ | (157,849) | ​ | ​ | (26,493) | ​ | ​ | 9,325 | ​ | ​ | 1,110,753 | ​
2020 | ​ | ​ | 1,056,375 | ​ | ​ | 484,122 | ​ | ​ | 447,571 | ​ | ​ | 63,051 | ​ | ​ | (256,345) | ​ | ​ | 3,419 | ​ | ​ | 829,949 | ​
(1) | Represents the grant date fair value of restricted stock awards earned and as reported in the “Stock Awards” column of the Summary Compensation Table for each applicable year. These shares were issued in March of the succeeding year.
(2) | Adjustments are equal to (i) the year-end fair value of restricted stock awards granted during the applicable year that are earned but not issued and therefore deemed outstanding and unvested as of the end of the year, (ii) the amount of the change in fair value as of the end of the applicable year (from the end of the prior fiscal year) of any restricted stock awards granted in prior years that are outstanding and unvested as of the end of the applicable year, and (iii) for restricted stock awards granted in prior years that vest in the applicable year, an amount equal to the change in fair value as of the vesting date (from the end of the prior fiscal year).
(3) | Restricted stock awards are valued using the market price of our stock. The closing market price of our stock was $93.14, $81.03, $95.55, $120.25, and $114.35 as of December 31, 2023, 2022, 2021, 2020, and 2019, respectively. The closing market price of our stock when the PEO and other NEOs’ restricted stock awards vested was $81.03 on January 1, 2023, $97.91 on April 1, 2023, $121.39 on July 1, 2023, $91.73 on October 1, 2023, $95.55 on January 1, 2022, $103.76 on April 1, 2022, $112.30 on July 1, 2022, $760.02 on October 1, 2022, $120.25 on January 1, 2021, $110.21 on April 1, 2021, $119.34 on July 1, 2021, $111.55 on October 1, 2021, $114.35 on January 1, 2020, $59.00 on April 1, 2020, $81.02 on July 1, 2020 and $86.88 on October 1, 2020.
(4) | Includes dividends paid and declared on outstanding and unvested shares as of December 31, 2023, 2022, 2021 and 2020. Dividends declared per common share were $1.72, $1.64, $1.46, and $0.32 for the fiscal years ended December 31, 2023, 2022, 2021 and 2020, respectively.
Company Selected Measure Name | Adjusted EBITDA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Named Executive Officers, Footnote |
1) | The PEO is Christopher J. Reading for each of the years presented. The non-PEO NEOs are Carey P. Hendrickson, Eric J. Williams, Graham D. Reeve, and Richard Binstein for the years 2023 and 2022, Carey P. Hendrickson, Eric J. Williams, Glenn D. McDowell, and Graham D. Reeve for 2021 and Carey P. Hendrickson, Lawrance W. MacAfee, Glenn D. McDowell, and Graham D. Reeve for 2020.
Peer Group Issuers, Footnote |
4) | Total Shareholder Return assumes that $100 was invested in our common stock and the common stock on each of the companies listed on The NYSE Heathcare Index (the Company’s Peer Group), on December 31, 2019, and that any dividends were reinvested.
PEO Total Compensation Amount | $ 3,372,377 | $ 2,408,584 | $ 4,143,576 | $ 2,961,147 |  |  |  |  |  |  |  |  |  |  |  |  |
PEO Actually Paid Compensation Amount | $ 3,822,626 | 1,859,559 | 3,275,545 | 2,446,657 |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment To PEO Compensation, Footnote |
5) | For a computation of compensation actually paid to PEO and average compensation actually paid to non-PE NEOs, please refer to the subsequent table.
The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table on page 31, to derive the compensation actually paid to the Company’s PEO and other NEOs.
| ​ | ​ | Adjustments | ​
Year | ​ | ​ | Summary Compensation Table Total ($) | ​ | ​ | Less: Reported Value of Stock Awards ($)(1) | ​ | ​ | Plus: Year End Fair Value of Restricted Stock Awards Granted During the Year ($)(2)(3) | ​ | ​ | Plus: Change in Fair Value of Outstanding and Unvested Restricted Stock Awards ($)(2)(3) | ​ | ​ | Plus: Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year ($)(2)(3) | ​ | ​ | Dividends paid on Unvested Restricted Stock Awards During the Fiscal Year ($)(4) | ​ | ​ | Compensation Actually Paid ($) | ​
PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
2023 | ​ | ​ | 3,372,377 | ​ | ​ | 1,632,482 | ​ | ​ | 1,508,868 | ​ | ​ | 288,036 | ​ | ​ | 235,956 | ​ | ​ | 49,871 | ​ | ​ | 3,822,626 | ​
2022 | ​ | ​ | 2,408,584 | ​ | ​ | 1,016,800 | ​ | ​ | 810,300 | ​ | ​ | (411,395) | ​ | ​ | 22,404 | ​ | ​ | 46,466 | ​ | ​ | 1,859,559 | ​
2021 | ​ | ​ | 4,143,576 | ​ | ​ | 2,120,100 | ​ | ​ | 1,911,000 | ​ | ​ | (613,844) | ​ | ​ | (81,371) | ​ | ​ | 36,284 | ​ | ​ | 3,275,545 | ​
2020 | ​ | ​ | 2,961,147 | ​ | ​ | 1,533,056 | ​ | ​ | 1,346,800 | ​ | ​ | 180,251 | ​ | ​ | (518,261) | ​ | ​ | 9,776 | ​ | ​ | 2,446,657 | ​
Non-PEO NEOs | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2023 | ​ | ​ | 1,722,785 | ​ | ​ | 816,241 | ​ | ​ | 754,434 | ​ | ​ | 108,759 | ​ | ​ | 76,874 | ​ | ​ | 18,679 | ​ | ​ | 1,865,290 | ​
2022 | ​ | ​ | 1,122,465 | ​ | ​ | 444,850 | ​ | ​ | 354,506 | ​ | ​ | (132,671) | ​ | ​ | 5,768 | ​ | ​ | 14,872 | ​ | ​ | 920,090 | ​
2021 | ​ | ​ | 1,454,841 | ​ | ​ | 706,539 | ​ | ​ | 537,469 | ​ | ​ | (157,849) | ​ | ​ | (26,493) | ​ | ​ | 9,325 | ​ | ​ | 1,110,753 | ​
2020 | ​ | ​ | 1,056,375 | ​ | ​ | 484,122 | ​ | ​ | 447,571 | ​ | ​ | 63,051 | ​ | ​ | (256,345) | ​ | ​ | 3,419 | ​ | ​ | 829,949 | ​
(1) | Represents the grant date fair value of restricted stock awards earned and as reported in the “Stock Awards” column of the Summary Compensation Table for each applicable year. These shares were issued in March of the succeeding year.
(2) | Adjustments are equal to (i) the year-end fair value of restricted stock awards granted during the applicable year that are earned but not issued and therefore deemed outstanding and unvested as of the end of the year, (ii) the amount of the change in fair value as of the end of the applicable year (from the end of the prior fiscal year) of any restricted stock awards granted in prior years that are outstanding and unvested as of the end of the applicable year, and (iii) for restricted stock awards granted in prior years that vest in the applicable year, an amount equal to the change in fair value as of the vesting date (from the end of the prior fiscal year).
(3) | Restricted stock awards are valued using the market price of our stock. The closing market price of our stock was $93.14, $81.03, $95.55, $120.25, and $114.35 as of December 31, 2023, 2022, 2021, 2020, and 2019, respectively. The closing market price of our stock when the PEO and other NEOs’ restricted stock awards vested was $81.03 on January 1, 2023, $97.91 on April 1, 2023, $121.39 on July 1, 2023, $91.73 on October 1, 2023, $95.55 on January 1, 2022, $103.76 on April 1, 2022, $112.30 on July 1, 2022, $760.02 on October 1, 2022, $120.25 on January 1, 2021, $110.21 on April 1, 2021, $119.34 on July 1, 2021, $111.55 on October 1, 2021, $114.35 on January 1, 2020, $59.00 on April 1, 2020, $81.02 on July 1, 2020 and $86.88 on October 1, 2020.
(4) | Includes dividends paid and declared on outstanding and unvested shares as of December 31, 2023, 2022, 2021 and 2020. Dividends declared per common share were $1.72, $1.64, $1.46, and $0.32 for the fiscal years ended December 31, 2023, 2022, 2021 and 2020, respectively.
Non-PEO NEO Average Total Compensation Amount | $ 1,722,785 | 1,122,465 | 1,454,841 | 1,056,375 |  |  |  |  |  |  |  |  |  |  |  |  |
Non-PEO NEO Average Compensation Actually Paid Amount | $ 1,865,290 | 920,090 | 1,110,753 | 829,949 |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Non-PEO NEO Compensation Footnote |
5) | For a computation of compensation actually paid to PEO and average compensation actually paid to non-PE NEOs, please refer to the subsequent table.
The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table on page 31, to derive the compensation actually paid to the Company’s PEO and other NEOs.
| ​ | ​ | Adjustments | ​
Year | ​ | ​ | Summary Compensation Table Total ($) | ​ | ​ | Less: Reported Value of Stock Awards ($)(1) | ​ | ​ | Plus: Year End Fair Value of Restricted Stock Awards Granted During the Year ($)(2)(3) | ​ | ​ | Plus: Change in Fair Value of Outstanding and Unvested Restricted Stock Awards ($)(2)(3) | ​ | ​ | Plus: Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year ($)(2)(3) | ​ | ​ | Dividends paid on Unvested Restricted Stock Awards During the Fiscal Year ($)(4) | ​ | ​ | Compensation Actually Paid ($) | ​
PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
2023 | ​ | ​ | 3,372,377 | ​ | ​ | 1,632,482 | ​ | ​ | 1,508,868 | ​ | ​ | 288,036 | ​ | ​ | 235,956 | ​ | ​ | 49,871 | ​ | ​ | 3,822,626 | ​
2022 | ​ | ​ | 2,408,584 | ​ | ​ | 1,016,800 | ​ | ​ | 810,300 | ​ | ​ | (411,395) | ​ | ​ | 22,404 | ​ | ​ | 46,466 | ​ | ​ | 1,859,559 | ​
2021 | ​ | ​ | 4,143,576 | ​ | ​ | 2,120,100 | ​ | ​ | 1,911,000 | ​ | ​ | (613,844) | ​ | ​ | (81,371) | ​ | ​ | 36,284 | ​ | ​ | 3,275,545 | ​
2020 | ​ | ​ | 2,961,147 | ​ | ​ | 1,533,056 | ​ | ​ | 1,346,800 | ​ | ​ | 180,251 | ​ | ​ | (518,261) | ​ | ​ | 9,776 | ​ | ​ | 2,446,657 | ​
Non-PEO NEOs | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2023 | ​ | ​ | 1,722,785 | ​ | ​ | 816,241 | ​ | ​ | 754,434 | ​ | ​ | 108,759 | ​ | ​ | 76,874 | ​ | ​ | 18,679 | ​ | ​ | 1,865,290 | ​
2022 | ​ | ​ | 1,122,465 | ​ | ​ | 444,850 | ​ | ​ | 354,506 | ​ | ​ | (132,671) | ​ | ​ | 5,768 | ​ | ​ | 14,872 | ​ | ​ | 920,090 | ​
2021 | ​ | ​ | 1,454,841 | ​ | ​ | 706,539 | ​ | ​ | 537,469 | ​ | ​ | (157,849) | ​ | ​ | (26,493) | ​ | ​ | 9,325 | ​ | ​ | 1,110,753 | ​
2020 | ​ | ​ | 1,056,375 | ​ | ​ | 484,122 | ​ | ​ | 447,571 | ​ | ​ | 63,051 | ​ | ​ | (256,345) | ​ | ​ | 3,419 | ​ | ​ | 829,949 | ​
(1) | Represents the grant date fair value of restricted stock awards earned and as reported in the “Stock Awards” column of the Summary Compensation Table for each applicable year. These shares were issued in March of the succeeding year.
(2) | Adjustments are equal to (i) the year-end fair value of restricted stock awards granted during the applicable year that are earned but not issued and therefore deemed outstanding and unvested as of the end of the year, (ii) the amount of the change in fair value as of the end of the applicable year (from the end of the prior fiscal year) of any restricted stock awards granted in prior years that are outstanding and unvested as of the end of the applicable year, and (iii) for restricted stock awards granted in prior years that vest in the applicable year, an amount equal to the change in fair value as of the vesting date (from the end of the prior fiscal year).
(3) | Restricted stock awards are valued using the market price of our stock. The closing market price of our stock was $93.14, $81.03, $95.55, $120.25, and $114.35 as of December 31, 2023, 2022, 2021, 2020, and 2019, respectively. The closing market price of our stock when the PEO and other NEOs’ restricted stock awards vested was $81.03 on January 1, 2023, $97.91 on April 1, 2023, $121.39 on July 1, 2023, $91.73 on October 1, 2023, $95.55 on January 1, 2022, $103.76 on April 1, 2022, $112.30 on July 1, 2022, $760.02 on October 1, 2022, $120.25 on January 1, 2021, $110.21 on April 1, 2021, $119.34 on July 1, 2021, $111.55 on October 1, 2021, $114.35 on January 1, 2020, $59.00 on April 1, 2020, $81.02 on July 1, 2020 and $86.88 on October 1, 2020.
(4) | Includes dividends paid and declared on outstanding and unvested shares as of December 31, 2023, 2022, 2021 and 2020. Dividends declared per common share were $1.72, $1.64, $1.46, and $0.32 for the fiscal years ended December 31, 2023, 2022, 2021 and 2020, respectively.
Compensation Actually Paid vs. Total Shareholder Return | Relationship between Pay and TSR The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs, the cumulative total stockholder return (“TSR”) on $100 invested in the Company at the close of the market on December 31, 2019, with dividends being reinvested on the date paid through December 31, 2023, and the cumulative TSR of the NYSE Health Care Index. The NYSE Health Care Index TSR is calculated in a similar manner as the Company’s TSR. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Net Income | Relationship between Pay and Net Income The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs and the Company’s net income. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Company Selected Measure | Relationship between Pay and Adjusted EBITDA The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs and the Company’s Adjusted EBITDA. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total Shareholder Return Vs Peer Group | Relationship between Pay and TSR The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs, the cumulative total stockholder return (“TSR”) on $100 invested in the Company at the close of the market on December 31, 2019, with dividends being reinvested on the date paid through December 31, 2023, and the cumulative TSR of the NYSE Health Care Index. The NYSE Health Care Index TSR is calculated in a similar manner as the Company’s TSR. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tabular List, Table | For the year ended December 31, 2023, the most important financial performance measure used by the Company to link executive compensation actually paid to the executive officers was Adjusted EBITDA. For the years ended December 31, 2022, 2021, and 2020, the most important financial performance measure used by the Company to link executive compensation actually paid to the executive officers was Operating Results, which is described in the accompanying footnotes below. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total Shareholder Return Amount | $ 81 | 71 | 84 | 105 |  |  |  |  |  |  |  |  |  |  |  |  |
Peer Group Total Shareholder Return Amount | 134 | 130 | 135 | 111 |  |  |  |  |  |  |  |  |  |  |  |  |
Net Income (Loss) | $ 37,220,000 | $ 43,407,000 | $ 57,924,000 | $ 52,491,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Company Selected Measure Amount | 77,717,000 | 73,661,000 | 73,780,000 | 70,017,000 |  |  |  |  |  |  |  |  |  |  |  |  |
PEO Name | Christopher J. Reading | Christopher J. Reading | Christopher J. Reading | Christopher J. Reading |  |  |  |  |  |  |  |  |  |  |  |  |
Share Price | $ 93.14 | $ 81.03 | $ 95.55 | $ 120.25 | $ 91.73 | $ 121.39 | $ 97.91 | $ 760.02 | $ 112.3 | $ 103.76 | $ 111.55 | $ 119.34 | $ 110.21 | $ 86.88 | $ 81.02 | $ 59 | $ 114.35
Common Stock, Dividends, Per Share, Declared | $ 1.72 | $ 1.64 | $ 1.46 | $ 0.32 |  |  |  |  |  |  |  |  |  |  |  |  |
Measure:: 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Name | Adjusted EBITDA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-GAAP Measure Description |
6) | For additional information regarding Adjusted EBITDA, please see Item 7 in the Company’s Form 10-K filed with the SEC on February 29, 2024.
Measure:: 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Other Measure | Relationship between Pay and Operating Results The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs and the Company’s After-tax Operating Results. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Performance Measure, Amount | 36,265,000 | 35,034,000 | 43,732,000 | 38,435,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Name | Operating Results |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-GAAP Measure Description |
3) | Operating Results, a non-GAAP measure, equals net income attributable to our stockholders less non-cash asset impairment charge, changes in revaluation of put-right liability, Relief Funds, changes in fair value of contingent earn-out consideration, and any allocations to non-controlling interests, all net of taxes. For additional information regarding Operating Results, please see Item 7 in the Company’s Form 10-K filed with the SEC on February 29, 2024.
PEO | Reported Value of Stock Awards [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | $ (1,632,482) | $ (1,016,800) | $ (2,120,100) | $ (1,533,056) |  |  |  |  |  |  |  |  |  |  |  |  |
PEO | Year End Fair Value of Restricted Stock Awards Granted During the Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 1,508,868 | 810,300 | 1,911,000 | 1,346,800 |  |  |  |  |  |  |  |  |  |  |  |  |
PEO | Change in Fair Value of Outstanding and Unvested Restricted Stock Awards [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 288,036 | (411,395) | (613,844) | 180,251 |  |  |  |  |  |  |  |  |  |  |  |  |
PEO | Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 235,956 | 22,404 | (81,371) | (518,261) |  |  |  |  |  |  |  |  |  |  |  |  |
PEO | Dividends Paid on Unvested Restricted Stock Awards During the Fiscal Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 49,871 | 46,466 | 36,284 | 9,776 |  |  |  |  |  |  |  |  |  |  |  |  |
Non-PEO NEO | Reported Value of Stock Awards [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | (816,241) | (444,850) | (706,539) | (484,122) |  |  |  |  |  |  |  |  |  |  |  |  |
Non-PEO NEO | Year End Fair Value of Restricted Stock Awards Granted During the Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 754,434 | 354,506 | 537,469 | 447,571 |  |  |  |  |  |  |  |  |  |  |  |  |
Non-PEO NEO | Change in Fair Value of Outstanding and Unvested Restricted Stock Awards [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 108,759 | (132,671) | (157,849) | 63,051 |  |  |  |  |  |  |  |  |  |  |  |  |
Non-PEO NEO | Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | 76,874 | 5,768 | (26,493) | (256,345) |  |  |  |  |  |  |  |  |  |  |  |  |
Non-PEO NEO | Dividends Paid on Unvested Restricted Stock Awards During the Fiscal Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | $ 18,679 | $ 14,872 | $ 9,325 | $ 3,419 |  |  |  |  |  |  |  |  |  |  |  |  |

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_CompActuallyPaidVsOtherMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_OtherPerfMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate dividends declared during the period for each share of common stock outstanding. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_CommonStockDividendsPerShareDeclared
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7 Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_ReportedValueOfStockAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_YearEndFairValueOfRestrictedStockAwardsGrantedDuringTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_ChangeInFairValueOfOutstandingAndUnvestedRestrictedStockAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_ChangesInFairValueOfRestrictedStockInPriorYearsThatVestedDuringTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_DividendsPaidOnUnvestedRestrictedStockAwardsDuringTheFiscalYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |